# Bausch + Lomb account plan

> Bausch + Lomb is an eye health company with about 400 products, $5,101 million FY2025 revenue and approximately 13,000 employees.

## At a glance

Bausch + Lomb is a fully integrated eye health business selling contact lenses, lens care, eye vitamins, prescription eye medications, intraocular lenses and surgical systems through direct sales forces and distributors. Headquartered in Vaughan, Ontario, it has approximately 13,000 employees, a presence in approximately 100 countries and 25 manufacturing facilities in 11 countries. FY2025 revenue was $5,101 million (+6%), with operating income of $113 million and a net loss attributable of $360 million. It is listed on the NYSE and TSX (BLCO) and Bausch Health held approximately 87% of the shares as of October 21, 2026, while it continues to evaluate completing the Separation.

## Business units

- **Vision Care** (57% of FY2025 revenue ($2,923 million)): Consumer eye care (PreserVision, Ocuvite, Biotrue, Renu, Lumify, Blink, Artelac) and contact lenses (SiHy Daily, ULTRA, Biotrue ONEday, PureVision). FY2025 revenue grew 7%; Q3 2026 revenue was $774 million, +5%, driven by daily SiHy and ULTRA lenses and by Lumify and Artelac.
- **Pharmaceuticals** (25% of FY2025 revenue ($1,284 million)): Proprietary and generic eye drugs for dry eye, glaucoma, inflammation, post-operative care and retinal disease, led by XIIDRA and MIEBO. Q3 2026 revenue was $367 million, +11%, with MIEBO up 42% to $119 million, while gross-to-net pressure on XIIDRA and MIEBO weighs on pricing.
- **Surgical** (18% of FY2025 revenue ($894 million)): Equipment, consumables and implants for cataract, corneal, vitreoretinal and refractive surgery (Stellaris Elite, VICTUS, Teneo, enVista IOLs). Profit fell 59% to $18 million in FY2025 after the March 2025 enVista recall; Q3 2026 revenue was $234 million, +9%, with premium IOLs up approximately 70%. Luc Bonnefoy is Surgical President.

## Strategic priorities

- **Vision 27 three-year plan**: Interim CEO Thomas J. Appio's priorities are improving profitability, meeting or exceeding the three-year plan targets and advancing the pipeline. The 2028 target is a 23% adjusted EBITDA margin.
- **Deleveraging**: Net leverage was 4.1x in Q3 2026 versus 5.7x a year earlier, with a target of 3.5x or better by end-2028; management calls delevering the highest priority.
- **SG&A savings and margin expansion**: Appio said there are opportunities to drive SG&A savings; the CFO cited product mix, network optimization and vertical integration for gross margin, and about 150 basis points of SG&A improvement year to date.
- **Pipeline and premium products**: Launches planned include ELIOS (U.S. by end-2026), SeeLyra (510k approval anticipated by end-2026), enVista Beyond EDOF (U.S. launch 2027), Lumify NXT (approval anticipated H1 2027) and a myopia-control lens study starting in Q4 2026.
- **Settling ownership**: Bausch Health continues to evaluate completing the Separation, which may be a monetization of its stake, a sale, a distribution to its shareholders or a combination.

## Latest results

In Q3 2026 revenue was $1.375 billion versus $1.281 billion, up 7% (about 8% at constant currency), with growth in all three segments. Adjusted EBITDA rose to $325 million from $243 million, a 23.6% margin, and net income attributable was $32 million versus a $28 million loss. Operating cash flow was $233 million and free cash flow $178 million, which the CFO called the strongest quarter of cash generation since the IPO. Nine-month revenue was $4,013 million, up 9%. Full-year 2026 guidance was raised for the third time to revenue of $5.450-5.550 billion and adjusted EBITDA excluding acquired IPR&D of $1.090-1.140 billion.

## Investments and deals

- **Recent acquisitions**: Whitecap Biosciences (January 2025) and a manufacturing facility in Mexico (December 2025), after Elios Vision and Trukera Medical (2024) and XIIDRA, Blink and AcuFocus (2023); XIIDRA cost a $1,750 million upfront payment.
- **Capital expenditure**: Capex of about $285 million is guided for 2026, after higher capex drove a $455 million investing outflow in 2025.
- **Refinancing**: A June 2025 package (an $800 million revolver, a $2,325 million term B loan and €675 million secured notes) was followed by a $2,802 million refinancing term loan due January 2031 in January 2026.
- **Digital and AI**: Orphia is an AI-powered digital health platform for eye care providers, and the company launched the Bausch + Lomb AI Academy for employees in 2025.

## Challenges and risks

- **High indebtedness**: Interest expense was $421 million in FY2025 and is guided at about $365 million for 2026; corporate ratings are in the B range.
- **Gross-to-net pressure**: Provisions reached 40.6% of gross product sales in Q3 2026, mainly from rebates on XIIDRA and MIEBO, and FY2025 net pricing cut revenue by $53 million.
- **Quality and manufacturing compliance**: The March 2025 enVista recall hit Surgical profit, and the Tampa, Florida plant received an FDA warning letter in September 2026, though the company expects no supply interruption.
- **Tariffs and policy**: Tariffs raised cost of goods sold in 2025, and a U.S. proclamation imposes a 100% tariff on patented pharmaceutical products, with exemptions.
- **Leadership and ownership uncertainty**: Brent Saunders left on October 12, 2026; the interim CEO also runs Bausch Health, which the 10-Q lists as a source of competing demands and possible conflicts of interest.

## What leadership says

> "Our third-quarter performance reflects the strength and breadth of the business, with growth across all three segments and continued expansion in profitability" — Thomas J. Appio, Chairman and Interim CEO, Q3 2026 results release, 28 October 2026

> "We have to reduce our debt." — Thomas J. Appio, Chairman and Interim CEO, Q3 2026 earnings call, 28 October 2026

> "we're not sacrificing innovation for metrics." — Brent Saunders, former Chairman and CEO, Q2 2026 earnings call, 29 July 2026

> "delevering is our highest priority" — Brent Saunders, former Chairman and CEO, Q2 2026 earnings call, 29 July 2026


## Where a supplier can help

- **SG&A efficiency**: The interim CEO's push for SG&A savings across selling, advertising and G&A opens doors for vendors that lower commercial or back-office cost per sale.
- **Manufacturing network and quality**: Network optimization, vertical integration, the new Mexico facility and the Tampa FDA warning letter point to needs in quality systems, compliance and manufacturing automation.
- **Tariff and supply chain resilience**: Tariff exposure and single-source products make supply chain planning, trade compliance and second-source manufacturing relevant.
- **Launch support for the pipeline**: ELIOS, SeeLyra, enVista Beyond and Lumify NXT launches need surgeon and eye care professional education, field enablement and market access support.
- **Digital and AI programmes**: Orphia and the AI Academy indicate demand for data, AI and digital health partners aligned with the Vision 27 plan.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Bausch + Lomb Corporation Annual Report on Form 10-K for the fiscal year ended December 31, 2025](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000007/blco-20251231.htm)

Annual report · 2026-02-18

- Bausch + Lomb is a pure-play global eye health company founded in 1853: ~13,000 employees, presence in ~100 countries, a portfolio of ~400 products; listed on NYSE/TSX (BLCO) since its May 2022 IPO and ~88% owned by Bausch Health Companies (BHC) as of February 11, 2026.
- FY2025 revenue was $5,101 million, up 6% from $4,791 million (5% at constant currency); operating income fell to $113 million from $162 million and the net loss attributable to the company widened to $360 million, driven by interest expense of $421 million.
- Three segments: Vision Care $2,923 million (57% of revenue, segment profit margin 29%), Pharmaceuticals $1,284 million (25%, margin 20%), Surgical $894 million (18%, margin 2% after the enVista IOL recall).
- Growth engines named in the filing: the dry eye portfolio (MIEBO, XIIDRA), Lumify, PreserVision, SiHy Daily and Bausch + Lomb ULTRA contact lenses, and premium IOLs on the enVista platform.
- The March 2025 voluntary recall of enVista IOLs (TASS reports traced to a vendor's raw material) hit Surgical profit (down 59% to $18 million); enVista sales were back at pre-recall levels in Q4 2025.
- Pipeline of over 60 R&D projects with ~900 R&D staff in 13 facilities: Lumify Luxe NDA, AREDS3 vitamins, myopia-control and bioactive contact lenses, dual-action lifitegrast, ocular pain and glaucoma neuroprotection drugs, ELIOS glaucoma laser, SeeLyra femtosecond system, SeeNova surgical platform.
- Gross-to-net deductions rose to 39.5% of gross product sales from 36.3%, mainly rebates on XIIDRA and MIEBO; McKesson and Cardinal Health each accounted for 10% of revenue.
- Debt: $3,695 million of variable-rate and $1,412 million of fixed-rate principal at December 31, 2025; ratings B1 (Moody's), B (S&P, Fitch). 2026 cash needs include ~$390 million of interest and ~$285 million of capex.
- Key risks: BHC control and the unresolved Separation (distribution or sale), tariffs, single-source suppliers (Lumify, Vyzulta, MIEBO, XIIDRA and others), gross-to-net pricing pressure, generic competition and leverage.

### [Bausch + Lomb Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000111/blco-20260930.htm)

Interim report · 2026-10-28

- Q3 2026 revenue was $1,375 million, up 7% (8% at constant currency); nine-month revenue $4,013 million, up 9%.
- Q3 segment revenue: Vision Care $774 million (+5%), Pharmaceuticals $367 million (+11%, driven by MIEBO), Surgical $234 million (+9%, driven by premium IOLs).
- Profitability turned: Q3 operating income $155 million (vs $95 million) and net income attributable to the company $32 million (vs a $28 million loss); Q3 segment margins Vision Care 32%, Pharmaceuticals 37%, Surgical 14%.
- Nine-month operating cash flow $418 million (vs $147 million); cash and restricted cash $515 million at September 30, 2026.
- Leadership change: Thomas J. Appio (CEO of Bausch Health) became interim CEO on October 12, 2026 after Brent Saunders' departure; Saunders receives a lump-sum cash payment of approximately $75 million. BHC owned approximately 87% of shares as of October 21, 2026.
- FDA issued a warning letter in September 2026 for the Tampa, Florida plant; production and supply continue.
- Pipeline: Lumify NXT NDA submitted (approval expected H1 2027), AREDS3 launched, ELIOS U.S. launch expected by end-2026, SeeLyra CE Mark obtained; the glaucoma neuroprotection eye drop missed its Phase 2 primary endpoint and will not advance in that form.
- $15 million of IEEPA tariff refunds received in the nine months; a 100% U.S. tariff on patented pharmaceuticals is flagged as a risk.

### [Bausch + Lomb Posts Strong Third-Quarter Performance, Raises Full-Year 2026 Guidance (Q3 2026 results release, Exhibit 99.1)](https://www.sec.gov/Archives/edgar/data/1860742/000186074226000108/ex991q3-2026.htm)

Interim report · 2026-10-28

- Q3 2026 revenue $1.375 billion, up 7% reported and 8% at constant currency; GAAP net income attributable $32 million; Adjusted EBITDA (and excluding acquired IPR&D) $325 million versus $243 million.
- Segments: Vision Care $774 million (+6% constant currency), Surgical $234 million (+9%), Pharmaceuticals $367 million (+11%).
- MIEBO revenue grew 42% to $119 million; LUMIFY grew 35%; daily SiHy contact lenses grew 24%; premium IOLs grew approximately 70%.
- Full-year 2026 guidance raised: revenue $5.450-5.550 billion (6.1-8.0% constant currency growth) and Adjusted EBITDA excluding acquired IPR&D $1.090-1.140 billion (from $1.025-1.075 billion).
- Q3 cash flow from operations $233 million versus $137 million; adjusted EPS $0.34 versus $0.18.
- Thomas J. Appio, chairman and interim CEO, says the company has delivered against its Investor Day commitments for four consecutive quarters and sees further room to improve execution and profitability.

### [Bausch + Lomb Q3 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/10/28/bausch-lomb-blco-q3-2026-earnings-call-transcript/)

Executive talk · Thomas J. Appio, Chairman and Interim Chief Executive Officer · 2026-10-28

- First call of Tom Appio as interim CEO (also CEO of Bausch Health), two weeks into the role; he declined to elaborate on Brent Saunders' departure beyond the press release and 8-K.
- His priorities: improve profitability and operate more effectively, meet or exceed the three-year Vision 2027 targets, keep advancing the pipeline with "rigorous" resource allocation; he will look for SG&A savings in selling, advertising and G&A.
- Q3: revenue $1.375 billion (+8% constant currency), adjusted EBITDA $325 million (+34%), margin 23.6%; free cash flow $178 million, the strongest cash quarter since the 2022 IPO.
- Net leverage fell to 4.1x from 5.7x a year earlier; 3.5x remains the target and the "number 1 priority", with investment second.
- Guidance raised for the third time in 2026: revenue $5.450-5.550 billion, adjusted EBITDA $1.090-1.140 billion, implying ~20.3% margin, about 130 basis points above the Investor Day target.
- Drivers: Miebo $119 million (+42%), Xiidra $89 million (+2%), Lumify $66 million (+38%), daily SiHy +25%, premium IOLs +75%; surgical equipment down 11% as the company favours system placements.
- Appio sees possible "gaps in the portfolio" to fill with accretive M&A; asked whether B+L should recombine with its parent, he said his focus is on performance.
- Pipeline: Project Halo bioactive lens, U.S. myopia study starting Q4 2026, oral tonabersat for early dry AMD (PK safety study early 2027), ELIOS approval hoped for by year-end, Phase 3 planning for the dual-action dry eye drop.

### [Bausch + Lomb Q2 2026 earnings call transcript](https://www.fool.com/earnings/call-transcripts/2026/08/07/bausch-lomb-blco-q2-2026-earnings-call-transcript/)

Executive talk · Brenton L. Saunders, Chairman and Chief Executive Officer · 2026-07-29

- Last earnings call of Brent Saunders as chairman and CEO (he left in October 2026): Q2 revenue $1.394 billion (+8% constant currency), adjusted EBITDA $246 million (+28%), margin 17.6%.
- Saunders' framing: "companies earn credibility through consistency"; four consecutive quarters of delivering against the November 2025 Investor Day three-year plan (Vision '27).
- 2026 guidance raised: revenue $5.440-5.540 billion, adjusted EBITDA $1.025-1.075 billion; deleveraging to 3.5x or better by end-2028 is the top capital priority, net leverage already 4.7x.
- Surgical +16%: premium IOLs +175%, premium now 13% of surgical revenue versus 6% in 2023; Surgical President Luc Bonnefoy says the curve "is not just deepening, it is compounding".
- Pharma +14%: Miebo $91 million (+44%), expected to "soon become the branded industry leader" in dry eye; Xiidra $87 million (+6%); Miebo Medicare coverage rose from 71% to 88%.
- Vision Care +4%: daily SiHy +16%, Biotrue +13%; U.S. consumer consumption tracks gasoline prices; Project Halo bioactive lens hoped for in the back half of 2028.
- Pipeline: ELIOS FDA submission filed; enVista Beyond narrowly missed some pivotal targets but a 2027 launch is still expected; Orphia, an AI-powered digital health platform for eye care practices, introduced.

## Questions about Bausch + Lomb

### What does Bausch + Lomb do?

It is an eye health company with about 400 products across Vision Care (contact lenses and consumer eye care), Pharmaceuticals (eye medications such as XIIDRA and MIEBO) and Surgical (cataract, vitreoretinal and refractive systems and implants).

### What is Bausch + Lomb's revenue?

FY2025 revenue was $5,101 million, up 6%. Q3 2026 revenue was $1.375 billion, and 2026 guidance is $5.450-5.550 billion.

### How many employees does Bausch + Lomb have?

Approximately 13,000, with a presence in approximately 100 countries, according to the FY2025 10-K.

### Who leads Bausch + Lomb?

Thomas J. Appio has been chairman and interim CEO since October 12, 2026, while remaining CEO of Bausch Health; Osama (Sam) Eldessouky is CFO.

### Who owns Bausch + Lomb?

Bausch Health held approximately 87% of the shares as of October 21, 2026 and continues to evaluate completing the Separation.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
